Editor’s Briefing: September 15, 2026

In Short. Novo’s “Novo-only” rebrand collided with a Tuesday morning walk-away from its $285 million Ascendis TransCon pact for a once-monthly semaglutide prodrug, while Scholar Rock’s Isembyld (apitegromab) cleared as the first muscle-targeted SMA add-on two weeks ahead of its listed September 30 PDUFA; Contineum’s J&J-partnered M1 antagonist missed another phase 2 primary in depression; Lilly killed an early obesity injectable that missed its internal bar as Corbus posted phase 1b CB1 data meant to look safer than monlunabant; Axoltis’s ALS peptide missed NfL; and manufacturing friction returned via GSK’s Dresden flu-site consolidation, AAM’s generics sustainability alarm, and Abbott’s $385 million Sturgis formula settlement.

---

Novo’s monthly GLP-1 retreat, hours into a rebrand

Novo told Fierce Biotech it would not detail why it terminated the November 2024 Ascendis collaboration built around Transient Conjugation (TransCon) for metabolic disease. The deal had licensed Novo into a lead once-monthly GLP-1 program with Ascendis eligible for up to $285 million in combined upfront, development, and regulatory milestones plus royalties, and further $77.5 million milestone pots if Novo expanded into other metabolic or cardiovascular candidates. Ascendis said it will now pursue TransCon Semaglutide itself as a once-monthly prodrug of the active ingredient in Wegovy. Novo’s spokesperson still framed less-frequent injections than current marketed options as an R&D focus, pursued “internally and in collaboration with external partners.” The walk-away lands the morning after Novo announced that everyday branding will drop “Nordisk” (legal name Novo Nordisk A/S unchanged) and turn the Apis bull logo to face right under a “Lasting Health Starts Now” line. Pipeline pruning under current leadership already includes giving up on candidates from the Inversago buy and ending further phase 3 work on ziltivekimab last week; Ascendis is the latest external monthly-GLP-1 bet to leave the board. (Fierce Biotech; Fierce Biotech; BioSpace)

Isembyld: muscle-first SMA, early PDUFA, Catalent hangover cleared

Free reporting overnight confirmed what FirstWord and STAT+ headlines flagged over the weekend: FDA approved Scholar Rock’s apitegromab as Isembyld for adults and children two and older who are already on SMN2-targeted therapy, calling it the first treatment aimed at SMA muscle atrophy rather than the motor neuron. Clearance came Friday, September 11, about two weeks ahead of the September 30 date still carried as Upcoming on pdufa.bio and in today’s regulatory packet. Phase 3 SAPPHIRE supported a 2.2-point Hammersmith Functional Motor Scale-Expanded improvement versus SMN2 therapy alone at one year, with more than one-third of Isembyld patients gaining three or more points; 98% elected a long-term extension. List price is about $310,000 per year for a typical patient (weight- and coverage-dependent). The label carries an unexpected bone-fracture warning that Leerink noted did not drive discontinuations and clustered in patients with pre-existing risk factors. The approval ends a year-long manufacturing detour: a September 2025 rejection tied to fill-finish problems at the Bloomington, Indiana Catalent site (later under Novo ownership), an Official Action Indicated classification, and Scholar Rock’s August 2026 removal of that plant from the U.S. application in favor of an alternate site. Shares jumped more than 23% after hours Friday on the news; BMO and Truist framed the label as broad across SMA types and ambulatory status, with peak-sales estimates in the low-billions range from Sell-side notes cited by BioSpace and BioPharma Dive. (Fierce Pharma; BioPharma Dive; BioSpace)

Contineum’s second midphase miss for J&J’s M1 bet

Johnson & Johnson’s Contineum-partnered JNJ-5120 (PIPE-307), an M1 receptor antagonist licensed in a deal that started with $50 million upfront and up to $1 billion in milestones when Contineum was still Pipeline Therapeutics, missed its primary endpoint in major depressive disorder. In a 107-patient phase 2, neither of two JNJ-5120 regimens beat placebo on a depression scale at Day 5. That follows an earlier MS midphase failure for the same asset. Contineum said J&J is still reviewing exploratory endpoints before deciding next steps. William Blair removed JNJ-5120 from its model (pre-readout success odds had been 35%) and reiterated that most of Contineum’s value sits in LPAR1 antagonist PIPE-791 for idiopathic pulmonary fibrosis, with read-through from Bristol Myers Squibb’s admilparant phase 3 expected early in the fourth quarter. After-hours Contineum fell only about 3.5%, consistent with that hierarchy. (Fierce Biotech)

Obesity R&D: Lilly’s early cut, Corbus’s CB1 re-entry card

Eli Lilly terminated phase 1 work on LY4064912 after the injectable or infusion candidate “didn't meet our high bar for continued development,” a spokesperson told Fierce; the 77-person trial in healthy volunteers and people with overweight or obesity across California, Texas, and Singapore is stopped. Lilly did not disclose the mechanism and has stopped listing early-stage projects publicly, while still pointing to a deep mid- and late-stage obesity slate topped by retatrutide (22.6% phase 3 weight loss cited; FDA submission planned for first-quarter 2027). Separately, Corbus’s oral CB1 inverse agonist CRB-913 posted phase 1b placebo-adjusted weight loss of up to 5% at Week 12, in the neighborhood of Novo’s older monlunabant phase 2a and oral Wegovy phase 3 figures Fierce referenced, without an efficacy plateau yet. The strategic pitch is neuropsychiatric tolerability after Sanofi’s Acomplia exit and Novo’s monlunabant phase 2 neuropsych signal: highest-dose CRB-913 rates of depression, anxiety, irritability, and insomnia ran 0% to 9.7%, and GI rates (except diarrhea) compared favorably to oral GLP-1s in the company’s cross-trial framing. Stock reaction was modest (+4% early). (Fierce Biotech; Fierce Biotech)

Axoltis perseveres after an ALS NfL miss

French biotech Axoltis’s phase 2 of synthetic peptide NX210c in 82 people with ALS missed its primary: no significant six-week change from baseline in blood neurofilament light chain versus placebo after four weeks of three-times-weekly 5 or 10 mg/kg dosing. The company highlighted non-significant NfL trend decreases at four months, motor-function scale reductions of 64% and 33% at the two doses (framed as slowing decline), and a significant drop in blood claudin-5 at 10 mg/kg that it reads as blood-brain-barrier restoration, arguing for broader neurodegenerative exploration. Primary miss, secondary narrative: classic biotech perseverance posture ahead of the next design choice. (Fierce Biotech)

Capacity, pricing, and a settlement echo

GSK will shutter egg-based flu vaccine manufacturing in Dresden and consolidate into Ste-Foy, Canada, citing excess capacity as demand for traditional egg-based shots falls; flu vaccine sales were already down 25% last year on U.S. competitive pressure, and a phase 3 mRNA flu candidate (FLUm3HA.b-3NA) is due to start this month. The Association for Accessible Medicines’ annual off-patent report warned of an “unsustainable, race to the bottom”: three buyers control about 90% of traditional generics volume, generic prices fell 5.8% last year after 6.3% in 2024, and generics filled 89% of U.S. prescriptions while representing 11.6% of spend. AAM again flagged biosimilar rebate pressure under a reimbursement model that still prefers brands. Abbott agreed to pay $385 million to resolve claims tied to the 2022 Sturgis, Michigan infant-formula contamination investigation and shortages (company denies fault or liability; DOJ closed its criminal probe under the current administration). On the advanced-therapy manufacturing desk, BioProcess International’s Barcelona Phacilitate coverage stressed Europe’s scientific edge outrunning commercialization alignment across regulation, HTA, reimbursement, and investment, while a BioPlan survey piece argued perfusion/continuous upstream is finally nearing broader adoption (single-use perfusion use roughly doubled since 2016 to 65.8% of respondents at any stage). (Fierce Pharma; BioSpace; STAT News; BioProcess International; BioProcess International)

IPO cash and a psychedelic access hearing

Electra Therapeutics filed to raise up to about $342 million (21.7 million shares at $14–$16; ~$297 million net at the midpoint, $342 million with the greenshoe) to fund ipsoprubart through an ongoing phase 2/3 in secondary hemophagocytic lymphohistiocytosis (about $220 million earmarked), plus earlier SIRP programs. Enrollment for the sHLH pivotal is still aimed at 2027. Separately, FDA’s Monday public hearing on psychedelic development, coming the same day Definium posted its third pivotal anxiety win (already briefed yesterday), turned less on whether approval is coming and more on who may supervise dosing: industry’s dosing-session-monitor model versus speakers urging required psychotherapy or psychiatrist oversight, and debate over a draft expectation that a non-physician lead monitor still have a physician reachable within 15 minutes. (Fierce Biotech; Fierce Biotech; BioSpace)

Workforce sidebar

A Massachusetts federal judge issued a preliminary injunction blocking DHS’s plan to replace “duration of status” visas for graduate students and postdocs with a four-year cap, finding the rule likely failed Administrative Procedure Act requirements while a fuller case proceeds. International researchers are roughly a quarter of U.S. life-science Ph.D. graduates and around 60% of postdocs, so the stay matters to lab capacity even before any final merits ruling. (STAT News)

What to watch

pdufa.bio (data through September 14) and today’s regulatory packet still list Ultragenyx UX111 (ABO-102, Sanfilippo A) for September 19, Merck Winrevair HYPERION label work for September 21, Mirum/Incyte zilurgisertib (FOP) for September 26, Biofrontera Ameluz for basal cell carcinoma for September 28, and a September 30 cluster with Novo Mim8 (denecimig) plus Scholar Rock apitegromab still marked Upcoming despite free-press confirmation of the Isembyld approval on September 11. Roche Tecentriq adjuvant MSI-H colon follows October 9; Merck/Daiichi I-DXd in extensive-stage SCLC is October 10; Roche Enspryng in thyroid eye disease is October 15. Telix’s TLX101-Px September 11 line remains at the front of the free calendar with a 0-days-due flag; treat status as unresolved on the free page until a decision note posts. STAT+ also flagged Vera’s Trutakna IgAN phase 3 finals this morning; free body not opened here.

Open mechanism and franchise questions from this tape: whether Ascendis can finance and differentiate monthly TransCon Semaglutide without Novo’s commercial engine; whether Isembyld’s myostatin block plus SMN2 backbone becomes standard add-on care despite fracture-language and a $310,000 list; whether J&J keeps any MDD path for JNJ-5120 after two midphase misses; whether CB1 can be rehabilitated on Corbus-class CNS rates or remains a graveyard; and whether egg-based flu capacity exits accelerate the shift to mRNA flu before GSK’s own phase 3 starts.